SURMOUNT-MAINTAIN (Horn 2026, 112 weeks): continued top dose -21.9% vs 5 mg step-down -16.6% vs placebo -9.9%, rescue therapy 8/25/67%: Aronne JAMA 2024
You've done the physical therapy
30 mg divided by 4 mg = 7.5 weeks
Cumulative benefit shows up as fewer missed training days, not as added muscle mass directly
[oai_citation:4PubMed]( [oai_citation:5PMC]( 4) Growth-hormone receptor (GHR) expression in tendon fibroblasts Gene-expression and protein studies found dose- and time-dependent up-regulation of GHR
To this end, we synthesized a number of permethylated quinolinium analogues[17] guided by in silico calculation of partition coefficient (clogP).[26] Addition of hydrophobic methyl group substitutions around the quinolinium scaffold (previously shown to negatively impact NNMT inhibitory activity)[17] only slightly improved membrane permeability via passive transport as indicated by the low, but non-zero, permeability values for 1,8-diMQ and 1,2,4,8-tetraMQ (Table 1)